Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma
NCT01688700Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2012
- Primary completion
- Sep 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01688700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01688700.